McMaster University
Structural and Functional Relevance of Intraluminal Mucus in Severe Asthma: Persistence During Biologic Therapy and Response to TSLP Blockade
Abstract
dc:description.abstractIntroduction: Mucus plugging (MP) in asthma arises from multiple mechanisms and contributes to airflow obstruction. Biologic therapies targeting type-2 (T2) inflammation can reduce MP, but the extent and clinical relevance of residual MP during treatment remain unclear. Tezepelumab, an anti-TSLP biologic, has been reported to reduce MP; however, its impact on lung ventilation has not been evaluated. This thesis characterizes MP in biologic-treated patients and investigates the effects of tezepelumab on lung ventilation, mucus plugs, and airway inflammation. Methods: Two complementary studies were conducted. Study 1 was a cross-sectional analysis comparing CT-visible mucus plugs in 33 biologic-treated and 37 biologic-naïve adults with severe asthma. A validation cohort undergoing clinically-acquired CT scans was also analyzed. CT-mucus score (MS), clinical, physiological, and inflammatory outcomes were assessed. Study 2 was a single-centre, randomized, double-blind, placebo-controlled trial of tezepelumab 210 mg in adults with moderate-to-severe asthma and T2 inflammation. The primary endpoint was change in pre-bronchodilator hyperpolarized 129Xe magnetic resonance imaging (MRI) ventilation defect percent (VDP). Secondary endpoints included CT-MS, lung physiology, T2 biomarkers, and patient-reported outcomes. Results: In Study 1, biologic-treated patients had lower CT-MS than biologic-naïve patients (4 [2-6.5] vs 7 [5.5-11]; p<0.001), although most treated patients had persistent MP despite therapy. Higher MS was associated with multiple adverse clinical and functional outcomes, but not consistently with T2 biomarkers. Similar associations were observed in the validation cohort. In Study 2, tezepelumab was associated with greater reductions in VDP (between-group difference -4.5%; p=0.008), CT-MS (between-group difference -3.0; p=0.03) and T2 biomarkers than placebo. VDP improvement was associated with changes in CT-MS and T2 biomarkers in treated individuals. Conclusions: CT-visible mucus plugs remain common and clinically relevant during biologic therapy. Tezepelumab improved regional ventilation alongside reductions in CT-MS and T2 inflammation. Baseline sputum TSLP was an exploratory candidate treatment-effect modifier.
Degree
thesis:*- Department dc:contributor.department
- Health Sciences
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Venegas Garrido, Carmen
- Advisor dc:contributor.advisor
-
- Nair, Parameswaran
Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- https://doi.org/10.71548/25571